On Dec 7, 2010, the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee gave a positive recommendation for the use of Contrave in the treatment of obesity and weight management, signalling a potentially major shift in attitude towards the disorder. Contrave, if finally approved by the FDA on Jan 31,2011, will be the first new weight-loss drug to be approved for 10 years. The drug is a combination of bupropion, an antidepressant used to help patients to quit smoking, and naltrexone, an opioid antagonist prescribed for alcohol and drug addiction, thought to affect the reward pathway (system in which behaviour is regulated by induction of pleasure).
展开▼
